- Home
- XTNT vs MCRB Comparison
XTNT vs MCRB Comparison
Compare XTNT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- MCRB
- Stock Information
- Founded
- XTNT N/A
- MCRB 2010
- Country
- XTNT United States
- MCRB United States
- Employees
- XTNT N/A
- MCRB N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- MCRB Health Care
- Exchange
- XTNT Nasdaq
- MCRB Nasdaq
- Market Cap
- XTNT 60.9M
- MCRB 65.5M
- IPO Year
- XTNT N/A
- MCRB 2015
- Fundamental
- Price
- XTNT $0.72
- MCRB $10.46
- Analyst Decision
- XTNT
- MCRB Hold
- Analyst Count
- XTNT 0
- MCRB 4
- Target Price
- XTNT N/A
- MCRB $73.67
- AVG Volume (30 Days)
- XTNT 79.3K
- MCRB 97.4K
- Earning Date
- XTNT 08-07-2025
- MCRB 08-12-2025
- Dividend Yield
- XTNT N/A
- MCRB N/A
- EPS Growth
- XTNT N/A
- MCRB N/A
- EPS
- XTNT N/A
- MCRB 8.98
- Revenue
- XTNT $122,298,000.00
- MCRB N/A
- Revenue This Year
- XTNT $11.64
- MCRB N/A
- Revenue Next Year
- XTNT $7.59
- MCRB N/A
- P/E Ratio
- XTNT N/A
- MCRB $1.24
- Revenue Growth
- XTNT 20.81
- MCRB N/A
- 52 Week Low
- XTNT $0.33
- MCRB $6.53
- 52 Week High
- XTNT $0.83
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- XTNT 67.35
- MCRB 65.23
- Support Level
- XTNT $0.60
- MCRB $7.17
- Resistance Level
- XTNT $0.78
- MCRB $11.58
- Average True Range (ATR)
- XTNT 0.05
- MCRB 0.80
- MACD
- XTNT 0.01
- MCRB 0.39
- Stochastic Oscillator
- XTNT 85.71
- MCRB 75.17
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.